ClinicalTrials.gg
Active, not recruitingNCT06387173Updated May 11, 2026

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer

An observational study in Early Stage Breast Carcinoma, sponsored by Jonsson Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Jonsson Comprehensive Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Jonsson Comprehensive Cancer Center.

Started
2024
with 1 other
Observational
3 of 46
1 open now
Primary completion
2027-01
later than 2 of 10 live
Registered
43rd of 46
by date

Among the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, this one is one of 2 that started in 2024, is one of 3 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Breast Neoplasms by Jonsson Comprehensive Cancer Center, or all of them as a file.
02

Study summary

This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To obtain observational real-life data of patients who choose this non-conventional treatment and to follow their outcomes.

OUTLINE: This is an observational study.

Patients have their medical records reviewed on study.

03

Conditions studied

  • Early Stage Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing cryoablation for breast cancer

Eligibility criteria

Inclusion Criteria:

  • Patients undergoing cryoablation for breast cancer
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2 participants (actual)

Groups and cohorts

  • Observational

    Patients have their medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

06

What researchers measure

Primary outcomes

  1. Prospectively track patients who undergo cryoablation for breast cancer and record post-treatment related events.

    record follow up of symptoms, reported complications, breast imaging findings, and results of any future biopsies related to cancer, and treatment of breast cancer.

    Time frame: five years from last participant enrollment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 35 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 26, 2024
StartActual
Jan 4, 2024
Primary completionEst.
Jan 3, 2027
CompletionEst.
Jan 3, 2099
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06387173
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Jan 4, 2024
Primary completion
Jan 3, 2027 (estimated)
Completion
Jan 3, 2099 (estimated)
Last update
May 11, 2026

Study contacts

Nimmi S Kapoor, MD
principal investigator · UCLA / Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion